drugset / Trial / NCT01195376

A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors

NCT01195376

Phase 1 Completed 35 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

In this study, BEZ235 will be administered to adult patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. The trial will confirmed the safety and tolerability and determine the MTD of BEZ235 in Japanese patients.

Timeline

Start
2010-10
Primary completion
2013-07
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Dactolisib Small molecule 400 mg
Subject Dactolisib Small molecule 1000 mg
Subject Dactolisib Small molecule 1200 mg
Subject Dactolisib Small molecule 1400 mg

Indications